Chasing the KRAS field, Quanta Therapeutics bags $50M for two 2024 clinical trials

Quanta Therapeutics will bring its KRAS inhibitors into the clinic next year with a fresh heap of $50.7 million from blue-chip investors as it looks to catch up to the KRAS leaders and take the difficult class into other mutations and broader areas of oncology.

While…